- Stocks
- Healthcare
- NASDAQ: ITCI

Price (delayed)

$75.27

Market cap

$7.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.87

Enterprise value

$7.28B

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this

The equity has surged by 91% since the previous quarter and by 89% year-on-year

ITCI's quick ratio has soared by 60% from the previous quarter and by 9% YoY

The debt has grown by 12% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

What are the main financial stats of ITCI

Market
Valuations
Earnings

Shares outstanding

105.67M

Market cap

$7.95B

Enterprise value

$7.28B

Price to earnings (P/E)

N/A

Price to book (P/B)

6.94

Price to sales (P/S)

13.83

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

12.89

Revenue

$564.53M

EBIT

-$83.4M

EBITDA

-$82.87M

Free cash flow

-$61.23M

Per share
Balance sheet
Liquidity

EPS

-$0.87

Free cash flow per share

-$0.59

Book value per share

$10.84

Revenue per share

$5.44

TBVPS

$12.73

Total assets

$1.32B

Total liabilities

$175.89M

Debt

$18.29M

Equity

$1.14B

Working capital

$1.1B

Debt to equity

0.02

Current ratio

7.81

Quick ratio

7.23

Net debt/EBITDA

8.17

Margins
Efficiency
Dividend

EBITDA margin

-14.7%

Gross margin

92.7%

Net margin

-14.9%

Operating margin

-19.9%

Return on assets

-9.6%

Return on equity

-11.5%

Return on invested capital

-16.9%

Return on capital employed

-7.2%

Return on sales

-14.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Intra-Cellular Therapies stock price performed over time

Intraday

-0.46%

1 week

1.14%

1 month

-4.35%

1 year

30.18%

YTD

5.1%

QTD

9.9%

How have Intra-Cellular Therapies's revenue and profit performed over time

Revenue

$564.53M

Gross profit

$523.44M

Operating income

-$112.49M

Net income

-$84.3M

Gross margin

92.7%

Net margin

-14.9%

The net margin has surged by 70% year-on-year and by 31% since the previous quarter

The operating margin has soared by 63% YoY and by 23% from the previous quarter

The gross profit has soared by 54% YoY and by 10% from the previous quarter

The revenue has soared by 54% YoY and by 10% from the previous quarter

What is Intra-Cellular Therapies's growth rate over time

What is Intra-Cellular Therapies stock price valuation

P/E

N/A

P/B

6.94

P/S

13.83

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

12.89

The EPS has soared by 55% YoY and by 25% from the previous quarter

The equity has surged by 91% since the previous quarter and by 89% year-on-year

ITCI's P/B is 26% below its last 4 quarters average of 9.4 but 2.5% above its 5-year quarterly average of 6.8

The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 1757.4 but 6% more than its last 4 quarters average of 13.1

The revenue has soared by 54% YoY and by 10% from the previous quarter

How efficient is Intra-Cellular Therapies business performance

The ROS has soared by 71% YoY and by 31% from the previous quarter

Intra-Cellular Therapies's ROA has soared by 61% YoY and by 37% from the previous quarter

The ROE has soared by 60% YoY and by 38% from the previous quarter

ITCI's return on invested capital is up by 49% year-on-year and by 24% since the previous quarter

What is ITCI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ITCI.

How did Intra-Cellular Therapies financials performed over time

Intra-Cellular Therapies's total assets has soared by 85% YoY and by 77% from the previous quarter

The total liabilities has soared by 65% YoY and by 19% from the previous quarter

The debt is 98% smaller than the equity

The equity has surged by 91% since the previous quarter and by 89% year-on-year

ITCI's debt to equity is down by 33% since the previous quarter and by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Pricing data from and IEX Cloud.